The novel p53 isoform “delta p53” is a misfolded protein and does not bind the p21 promoter site

The tumor suppressor p53 can be expressed as different isoforms because of promoter selection and mRNA editing. One isoform, “delta p53” (Δp53), results from what would be an unusual alternative splicing of exons 7/8 of the p53 gene, conserving the reading frame and generating a novel protein with proposed transcriptional activity essential for the intra S‐phase checkpoint. Here, we show that the deletion of the 66 residues that correspond to strand β10 and the C‐terminal helix of the core domain and the interconnecting linker to the tetramerization domain occurring in the Δp53 isoform leads to a misfolded and unstable protein, prone to form soluble aggregates, which does not bind the p21 promoter site. The complex of coexpressed Δp53 and flp53 is soluble in vitro and binds poorly to DNA. Our results provide a structural explanation for the dominant‐negative effect of Δp53 and its lack of transcriptional activity.

[1]  A. Fersht,et al.  Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain , 2008, Proceedings of the National Academy of Sciences.

[2]  L. Ellisen,et al.  p63 and p73 in human cancer: defining the network , 2007, Oncogene.

[3]  A. Fersht,et al.  Quaternary structures of tumor suppressor p53 and a specific p53–DNA complex , 2007, Proceedings of the National Academy of Sciences.

[4]  Dmitri I. Svergun,et al.  Upgrade of the small-angle X-ray scattering beamline X33 at the European Molecular Biology Laboratory, Hamburg , 2007 .

[5]  A. Fersht,et al.  Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.

[6]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[7]  R. Poon,et al.  The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. , 2007, Cancer research.

[8]  M. Garcia-Alai,et al.  High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines. , 2007, Biochemistry.

[9]  Xiang-Dong Fu,et al.  Splicing oncogenes , 2007, Nature Structural &Molecular Biology.

[10]  S. Geisler,et al.  Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters , 2006, Molecular Cancer.

[11]  A. Fersht,et al.  Structural basis for understanding oncogenic p53 mutations and designing rescue drugs , 2006, Proceedings of the National Academy of Sciences.

[12]  Sebastian Mayer,et al.  Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains* , 2006, Journal of Biological Chemistry.

[13]  Ronen Marmorstein,et al.  Structure of the p53 Core Domain Dimer Bound to DNA*♦ , 2006, Journal of Biological Chemistry.

[14]  D. Lane,et al.  p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress , 2006, Cell Death and Differentiation.

[15]  Antonina Andreeva,et al.  Core domain interactions in full-length p53 in solution , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Alan R. Fersht,et al.  Solution structure of p53 core domain: Structural basis for its instability , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Manfredi,et al.  The continuing saga of p53--more sleepless nights ahead. , 2005, Molecular cell.

[18]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[19]  W. Deppert,et al.  A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint , 2005, Cell.

[20]  A. Fersht,et al.  Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations* , 2005, Journal of Biological Chemistry.

[21]  K. Harms,et al.  The C Terminus of p53 Family Proteins Is a Cell Fate Determinant , 2005, Molecular and Cellular Biology.

[22]  A. Fersht,et al.  Cooperative binding of tetrameric p53 to DNA. , 2004, Journal of molecular biology.

[23]  M. Garcia-Alai,et al.  The HPV16 E7 viral oncoprotein self-assembles into defined spherical oligomers. , 2004, Biochemistry.

[24]  Dmitri I. Svergun,et al.  PRIMUS: a Windows PC-based system for small-angle scattering data analysis , 2003 .

[25]  Martin Vingron,et al.  Increase of functional diversity by alternative splicing. , 2003, Trends in genetics : TIG.

[26]  A. Fersht,et al.  Stability and folding of the protein complexes of barnase. , 2000, European journal of biochemistry.

[27]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[28]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[29]  A. Fersht,et al.  Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Fersht,et al.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain , 1998, The EMBO journal.

[31]  G. Marius Clore,et al.  Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.

[32]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[33]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[34]  T. Nilsen,et al.  RNA-RNA interactions in the spliceosome: Unraveling the ties that bind , 1994, Cell.

[35]  Dmitri I. Svergun,et al.  Determination of the regularization parameter in indirect-transform methods using perceptual criteria , 1992 .

[36]  V. Rotter,et al.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis , 1990, Molecular and cellular biology.

[37]  A. Ginsburg,et al.  The use of 4-(2-pyridylazo)resorcinol in studies of zinc release from Escherichia coli aspartate transcarbamoylase. , 1985, Analytical biochemistry.

[38]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .

[39]  M. Brillouin,et al.  La diffraction des rayons X aux très petits angles: application a l'étude de phénomènes ultramicroscopiques , 1939 .

[40]  A. Guinier,et al.  La diffraction des rayons X aux très petits angles : application à l'étude de phénomènes ultramicroscopiques , 1939 .